bjh

british journal of haematology

Volume 130, 2005 Pages 1–982

Issue 1, July-I 2005

Images in Haematology

1 **Peritoneal haematopoiesis in acute panmyelosis with myelofibrosis**
G. Metzgeroth, A. Reiter, W. Back, M. Anders, R. Hehlmann and J. Hastka

2 **Disseminated *Penicillium marneffei* infection**
E. S. K. Ma and P. L. Ho

Reviews

3 **The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults**
P. Harrison

11 **Red cell pyruvate kinase deficiency: molecular and clinical aspects**
A. Zanella, E. Fermo, P. Bianchi and G. Valentini

Haematological Malignancy

26 **Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia**
F. W. van Delft, T. Bellotti, Z. Luo, L. K. Jones, N. Patel, O. Yiannikouris, A. S. Hill, M. Hubank, H. Kempski, D. Fletcher, T. Chaplin, N. Foot, B. D. Young, I. M. Hann, A. Gammerman and V. Saha

36 **Interphase fluorescence *in situ* hybridization with an *IGH* probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia**
G. S. Nowakowski, G. W. Dewald, J. D. Hoyer, S. F. Paternoster, K. J. Stockero, S. R. Fink, S. A. Smoley, E. D. Remstein, R. L. Phyliky, T. G. Call, T. D. Shanafelt, N. E. Kay and C. S. Zent

43 **FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia**
G. F. Torelli, A. Guarini, A. Porzia, S. Chiaretti, C. Tatarelli, D. Diverio, R. Maggio, A. Vitale, J. Ritz and R. Foa

51 **Engraftment of NOD/SCID/γc^{null} mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia**
Y. Nakamura, M. Ito, T. Yamamoto, X. Y. Yan, H. Yagasaki, Y. Kamachi, K. Kudo and S. Kojima

58 **Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia**
R. Schillaci, A. Galeano, D. Becu-Villalobos, O. Spinelli, S. Sapia and R. F. Bezares

67 **Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial**
A. Roy, A. Cargill, S. Love, A. V. Moorman, S. Stoneham, A. Lim, P. J. Darbyshire, D. Lancaster, I. Hann, T. Eden and V. Saha

76 **Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin**
O. Bock, G. Loch, U. Schade, G. Büsche, R. von Wasielewski, B. Wiese and H. Kreipe

Short reports

83 **CD34$^+$ cell selection is required to assess *HOXA9* expression levels in patients with myelodysplastic syndrome**
S. Heinrichs, J. N. Berman, T. M. Ortiz, S. M. Kornblau, D. S. Neuberg, E. H. Estey and A. T. Look

87 **Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders**
S. D. J. Gibbs, D. A. Westerman, C. McCormack, J. F. Seymour and H. M. Prince

92 **Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development**
M. C. Sirianni, F. Libi, M. Campagna, D. Rossi, D. Capello, G. Sciaranghella, A. Carbone, C. Simonelli, P. Monini, G. Gaidano and B. Ensoli

96 **Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study**
P. Ljungman, H. Nahi and A. Linde

Transplantation

99 **Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia**
J. Zanis-Neto, M. E. D. Flowers, C. R. Medeiros, M. A. Bitencourt, C. M. Bonfim, D. C. Setúbal, V. Funke, J. Sanders, H. J. Deeg, H. P. Kiem, P. Martin, W. Leisenring, R. Storb and R. Pasquini

Platelets, Haemostasis and Thrombosis

107 **Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands**
K. van Dijk, K. Fischer, J. G. van der Bom, E. Scheibel, J. Ingerslev and H. M. van den Berg

113 **Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation**
M. Cugno, P. Agostoni, D. Mari, P. L. Meroni, L. Gregorini, M. Bussotti, G. B. Anguissola, F. Donatelli and J. Nussberger

Haemopoiesis and Leucocytes

121 **Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor**
M. O. Arcasoy and X. Jiang

Red Cells and Iron

130 **A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice**
A. van Royen-Kerkhof, E. A. M. Sanders, V. Walraven, M. Voorhorst-Ogink, E. Saeland, J. L. Teeling, A. Gerritsen, M. A. van Dijk, W. Kuis, G. T. Rijkers, L. Vitale, T. Keler, S. E. McKenzie, J. H. W. Leusen and J. G. J. van de Winkel

138 **The measurement of urinary hydroxyurea in sickle cell anaemia**
R. N. Dalton, C. Turner, M. Dick, S. E. Height, M. Awogbade, B. Inusa, I. Okpala, S. O'Driscoll, S. L. Thein and D. C. Rees

Correspondence

145 **Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII – clarification of Kogenate inhibitor data**
P. Larson

146 **Response to Larson**
A. Gringeri

147 **The NF-κB pathway and the successful application of anti-inflammatory and angiostatic therapy in Langerhans' cell histiocytosis**
R. E. Brown

148 **Factors predicting development of chronic disease in Nordic children with acute onset of idiopathic thrombocytopenic purpura**
S. Rosthøj, I. Hedlund-Treutiger, J. Rajantie and B. Zeller on behalf of the Nordic Society for Paediatric Haematology and Oncology Idiopathic Thrombocytopenic Purpura Working Group

150 **Response to Rosthøj *et al***
M. Bruin, M. Bierings, C. Uiterwaal, R. R. Tamminga and M. de Haas

Issue 2, July-II 2005

Images in Haematology

151 **Extranodal mantle cell lymphoma in a prolapsed ileostomy stump**
H. Robinson and N. Rymes

152 **Transfusion-related acute lung injury complicating acute myeloid leukaemia therapy**
J. S. McDerra, R. J. Lush and A. Pope

Reviews

153 **Essential thrombocythaemia: challenges and evidence-based management**
C. N. Harrison

166 **Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia**
J. Nachman

Guideline

174 **Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis**
M. F. McMullin, D. Bareford, P. Campbell, A. R. Green, C. Harrison, B. Hunt, D. Oscier, M. I. Polkey, J. T. Reilly, E. Rosenthal, K. Ryan, T. C. Pearson and B. Wilkins on behalf of the General Haematology Task Force of the British Committee for Standards in Haematology

Haematological Malignancy

196 **Impact of *FLT3* mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia**
F. Kuchenbauer, C. Schoch, W. Kern, W. Hiddemann, T. Haferlach and S. Schnittger

203 **Rapid and sensitive detection of internal tandem duplication and activating loop mutations of *FLT3***
K. I. Mills, A. F. Gilkes, V. Walsh, M. Sweeney and R. Gale

209 **Hypermethylation of the suppressor of cytokine signalling-1 (*SOCS-1*) in myelodysplastic syndrome**
K. Brakensiek, F. Länger, B. Schlegelberger, H. Kreipe and U. Lehmann

218 **Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcγRIII (CD16)**
J. Bruenke, K. Barbin, S. Kunert, P. Lang, M. Pfeiffer, K. Stieglmaier, D. Niethammer, B. Stockmeyer, M. Peipp, R. Repp, T. Valerius and G. H. Fey

229 **Der(6)t(1;6)(q21–23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia**
D. Dingli, F. H. Grand, V. Mahaffey, J. Spurbeck, F. M. Ross, A. E. Watmore, J. T. Reilly, N. C. P. Cross, G. W. Dewald and A. Tefferi

233 **Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow**
E. Sakhinia, M. Faranghpour, J. A. Liu Yin, G. Brady, J. A. Hoyland and R. J. Byers

Transplantation

249 **Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation**
P. Corti, C. Peters, A. Balduzzi, B. Bertagnolio, A. Biondi, C. Bugarin, M. Dassi, F. Furlan, G. Gaipa, D. Longoni, O. Maglia, R. Parini, P. Perseghin, C. Uderzo, G. Uziel, G. Masera and A. Rovelli

256 **Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation**
D. F. Claxton, C. Ehmann and W. Rybka

265 **Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial**
G. Reich, O. A. Cornely, M. Sandherr, T. Kubin, S. Krause, H. Einsele, E. Thiel, T. Bellaire, B. Dörken and G. Maschmeyer

Short report 271 **Role of extracorporeal photochemotherapy in patients with refractory chronic graft-*versus*-host disease**
P. Rubegni, A. Cuccia, P. Sbano, G. Cevenini, M. R. Carcagnì, G. D'Ascenzo, G. De Aloe, S. Guidi, P. Guglielmetti, G. Marotta, F. Lauria, A. Bosi and M. Fimiani

Haemopoiesis and Leucocytes

276 ***In vivo* haematopoietic potential of human neural stem cells**
G. Almeida-Porada, K. Crapnell, C. Porada, B. Benoit, H. Nakauchi, P. Quesenberry and E. D. Zanjani

284 **Immaturity of IL-18 gene expression and protein production in cord blood (CB) *versus* peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function**
P. Satwani, J. Ayello, C. van de Ven, A. F. O'Neill, L. L. Simpson, L. Baxi and M. S. Cairo

Short report 293 **The use of digital 'virtual slides' in the quality assessment of haematological morphology: results of a pilot exercise involving UK NEQAS(H) participants**
J. Burthem, M. Brereton, J. Ardern, L. Hickman, L. Seal, A. Serrant, C. V. Hutchinson, E. Wells, P. McTaggart, B. De la Salle, J. Parker-Williams and K. Hyde

Red Cells and Iron

297 **Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia**
D. C. Rees, A. Iolascon, M. Carella, A. S. O'Marcaigh, J. R. Kendra, S. N. Jowitt, J. K. Wales, A. Vora, M. Makris, N. Manning, A. Nicolaou, J. Fisher, A. Mann, S. J. Machin, P. T. Clayton, P. Gasparini and G. W. Stewart

Transfusion

310 **Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgM**
J. M. G. Larkin and C. D. Porter

Correspondence

318 **Uptake of high-dose therapy and peripheral blood stem cell transplantation in myeloma patients < 65 years – the role of the myeloma multi-disciplinary team**
K. Saravanamuttu, J. L. Byrne, C. Williams, E. P. Das-Gupta, V. Tringham and N. H. Russell

319 **Reply to Saravanamuttu *et al*: Uptake of high dose therapy and peripheral blood stem cell transplantation in myeloma patients < 65 years – the role of the myeloma multi-disciplinary team**
T. C. M. Morris, M. Velangi, G. Jackson, D. Marks and L. Ranaghan

320 **Point of care testing by health care professionals: current practice amongst the UK National External Quality Assessment Scheme Participants**
D. P. Kitchen, S. Kitchen, I. Jennings, T. A. L. Woods, I. D. Walker and F. E. Preston

Issue 3, August-I 2005

Images in Haematology

323 **Lymphoma and malignant vasovagal syndrome**
V. Venkatraman, L. Lee and D. V. Nagarajan

324 **Much ado about nothing: silent brain lesions in T-ALL**
M. La Spina and G. Russo

Reviews

325 **Diagnostic criteria for monoclonal B-cell lymphocytosis**
G. E. Marti, A. C. Rawstron, P. Ghia, P. Hillmen, R. S. Houlston, N. Kay, T. A. Schleinitz and N. Caporaso on behalf of The International Familial CLL Consortium

333 **Perinatal stroke – risk factors and management**
E. A. Chalmers

344 **Immunotherapy in multiple myeloma – possibility or probability?**
S. J. Harrison and G. Cook

Haematological Malignancy

363 **Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens**
K. M. Ardeshna, N. Kakouros, W. Qian, M. G. Powell, N. Saini, S. D'Sa, S. Mackinnon, P. J. Hoskin, A. H. Goldstone and D. C. Linch

373 **Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors**
G. R. Angstreich, W. Matsui, C. A. Huff, M. S. Vala, J. Barber, A. L. Hawkins, C. A. Griffin, B. D. Smith and R. J. Jones

382 **Serological identification of adult T-cell leukaemia-associated antigens**
M. Hishizawa, K. Imada, T. Sakai, M. Ueda, T. Hori and T. Uchiyama

Short report 391 **Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres**
A. M. Ferraris, N. Pujic, R. Mangerini, D. Rapezzi, A. Gallamini, O. Racchi, S. Casciaro and G. F. Gaetani

Transplantation

394 **Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-*versus*-host disease after allogeneic transplantation**
J. A. Pérez-Simón, M. Díez-Campelo, R. Martino, S. Brunet, Á. Urbano, M. D. Caballero, Á. de León, D. Valcárcel, E. Carreras, M. C. del Cañizo, J. López-Fidalgo, J. Sierra and J. F. San Miguel

404 **Transient familial haemophagocytic lymphohistiocytosis reactivation post-CD34 haematopoietic stem cell transplantation**
H. Almousa, M. Ouachée-Chardin, C. Picard, I. Radford-Weiss, S. Caillat-Zucman, M. Cavazzana-Calvo, S. Blanche, G. de Saint Basile, F. Le Deist and A. Fischer

409 **Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-*versus*-host disease**
D. R. Couriel, R. Saliba, M. P. Escalón, Y. Hsu, S. Ghosh, C. Ippoliti, K. Hicks, M. Donato, S. Giralt, I. F. Khouri, C. Hosing, M. J. de Lima, B. Andersson, J. Neumann and R. Champlin

Short report 418 **Identification of APOBEC3B as a potential target for the graft-*versus*-lymphoma effect by SEREX in a patient with mantle cell lymphoma**
M. Hishizawa, K. Imada, T. Sakai, M. Ueda and T. Uchiyama

Platelets, Haemostasis and Thrombosis

422 **Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study**
E. Santagostino, M. E. Mancuso, A. Rocino, G. Mancuso, M. G. Mazzucconi, A. Tagliaferri, M. Messina and P. Mannuccio Mannucci

Haemopoiesis and Leucocytes

428 **AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication**
S. Takahashi, H. Harigae, J. Kameoka, T. Sasaki and M. Kaku

Red Cells and Iron

437 **Health-related quality of life in children with sickle cell disease: child and parent perception**
J. A. Panepinto, K. M. O'Mahar, M. R. DeBaun, F. R. Loberiza and J. P. Scott

445 **Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension**
R. F. Machado, S. Martyr, G. J. Kato, R. J. Barst, A. Anthi, M. R. Robinson, L. Hunter, W. Coles, J. Nichols, C. Hunter, V. Sachdev, O. Castro and M. T. Gladwin

Short report 454 **A novel 33·3 kb deletion (- -KOL) in the alpha-globin gene cluster: a brief report on deletional alpha-thalassaemia in the heterogeneous eastern Indian population**
A. A. Sarkar, S. Banerjee, S. Chandra, M. Ghosh, D. Banerjee, M. D. Choudhury, M. Das and U. B. Dasgupta

Correspondence

458 **Different fatherhood as a possible explanation for difficult pedigrees in coagulation defects: only 'mater semper certa est'**
A. Girolami, S. Vettore, E. Bortoletto and A. M. Lombardi

459 **Confirmation of paternity suggests a new mutation in the factor VII gene: 'Pater certus quouque est' - Response to Girolami *et al***
J. Hewitt, J. N. M. Ballard, T. N. Nelson, V. C. Smith, T. A. M. Griffiths, S. Pritchard, J. K. Wu, L. D. Wadsworth, B. Casey and R. T. A. MacGillivray

460 **Percentage of CD34$^+$ cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count**
V. Elliot, D. Marin, D. Horncastle, K. Elderfield, J. F. Apperley, I. A. Lampert and K. Naresh

462 **The Y/C1584 mutation of von Willebrand factor in type 2M von Willebrand disease: frequency and clearance of von Willebrand factor**
C. M. Millar, A. F. Riddel, A. Griffioe, P. V. Jenkin and S. A. Brown

463 **Transfusion-related acute lung injury (TRALI)**
S. J. Urbaniak

464 **Transfusion-related acute lung injury – response to Urbaniak**
J. P. Quinn and P. T. Murphy

465 **Corrigendum**

Issue 4, August-II 2005

Images in Haematology

467 **Bone marrow necrosis**
I. Miyoshi, M. Daibata, Y. Ohtsuki and H. Taguchi

468 **Air embolism simulating atypical pneumonia**
O. Penack, K.-J. Wolf and L. Uharek

Reviews

469 **Normal and leukaemic stem cells**
D. Bonnet

480 **Continuing challenges in childhood non-Hodgkin lymphoma**
R. Pinkerton

489 **Philadelphia positive acute lymphoblastic leukaemia of childhood**
L. K. Jones and V. Saha

Haematological Malignancy

501 **Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death**
G. V. Georgakis, Y. Li, R. Humphreys, M. Andreeff, S. O'Brien, M. Younes, A. Carbone, V. Albert and A. Younes

511 **Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia**
M. Dungerwalla, N. Osuji, A. D. Waldman, F. Al Jehani, A. Mehta, R. Taylor, A. Wotherspoon, G. Cogill and E. Matutes

516 **Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways**
E. G. Rizzatti, R. P. Falcão, R. A. Panepucci, R. Proto-Siqueira, W. T. Anselmo-Lima, O. K. Okamoto and M. A. Zago

527 ***Viscum album* agglutinin-I induces apoptosis and degradation of cytoskeletal proteins via caspases in human leukaemia eosinophil AML14.3D10 cells: differences with purified human eosinophils**
V. Lavastre, S. Chiasson, H. Cavalli and D. Girard

536 **Comparison of CHOP *versus* CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma**
C. Burton, P. Smith, G. Vaughan-Hudson, W. Qian, P. Hoskin, D. Cunningham, B. Hancock and D. Linch

542 **Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival**
R. Lovell, J. A. Dunn, G. Begum, N. J. Barth, T. Plant, P. A. Moss, M. T. Drayson and G. Pratt on behalf of the Working Party on Leukaemia in Adults (part of the National Cancer Research Institute Haematological Oncology Clinical Studies Group)

549 **The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience**
M. Gentile, F. R. Mauro, E. Calabrese, M. S. De Propris, E. Giammartini, F. Mancini, M. L. Milani, A. Guarini and R. Foà

Short report 558 **Zoledronate synergises with imatinib mesylate to inhibit Ph^+ primary leukaemic cell growth**
H. Segawa, S. Kimura, J. Kuroda, K. Sato, A. Yokota, E. Kawata, Y. Kamitsuji, E. Ashihara, T. Yuasa, Y. Fujiyama, O. G. Ottmann and T. Maekawa

Transplantation

561 **Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms**
N. Murashige, M. Kami, Y. Kishi, S.-W. Kim, M. Takeuchi, K. Matsue, Y. Kanda, M. Hirokawa, Y. Kawabata, T. Matsumura, E. Kusumi, N. Hirabayashi, K. Nagafuji, R. Suzuki, K. Takeuchi and K. Oshimi

568 **Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-*versus*-host disease**
M. Schmidt-Hieber, T. Fietz, W. Knauf, L. Uharek, W. Hopfenmüller, E. Thiel and I. W. Blau

575 **Impact of human leucocyte antigen mismatch on graft-*versus*-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors**
T. Teshima, K. Matsuo, K. Matsue, F. Kawano, S. Taniguchi, M. Hara, K. Hatanaka, M. Tanimoto, M. Harada, S. Nakao, Y. Abe, A. Wake, T. Eto, Y. Takemoto, M. Imamura, S. Takahashi, Y. Ishida, Y. Kanda, M. Kasai and Y. Takaue

588 **High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study**
R. Fenk, P. Schneider, M. Kropff, A. N. Huenerlituerkoglu, U. Steidl, C. Aul, B. Hildebrandt, R. Haas, A. Heyll and G. Kobbe for the West German Myeloma Study Group

595 **Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation**
B. Kampmann, D. Cubitt, T. Walls, P. Naik, M. Depala, S. Samarasinghe, D. Robson, A. Hassan, K. Rao, H. Gaspar, G. Davies, A. Jones, C. Cale, K. Gilmour, M. Real, M. Foo, N. Bennett-Rees, A. Hewitt, P. Amrolia and P. Veys

604 **^{188}Re or ^{90}Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study**
M. Ringhoffer, N. Blumstein, B. Neumaier, G. Glatting, S. von Harsdorf, I. Buchmann, M. Wiesneth, J. Kotzerke, T. Zenz, A. K. Buck, P. Schauwecker, S. Stilgenbauer, H. Döhner, S. N. Reske and D. Bunjes

Platelets, Haemostasis and Thrombosis

614 **C-reactive protein and D-dimer with clinical probability score in the exclusion of pulmonary embolism**
N. Steeghs, R. J. Goekoop, R. W. L. M. Niessen, G. J. P. M. Jonkers, H. Dik and M. V. Huisman

620 **Genotype–phenotype correlation in MYH9-related thrombocytopenia**
F. Dong, S. Li, N. Pujol-Moix, N. L. C. Luban, S. W. Shin, J. H. Seo, A. Ruiz-Saez, J. Demeter, S. Langdon and M. J. Kelley

Red Cells and Iron

628 **Clinical and molecular variability in congenital dyserythropoietic anaemia type I**
H. Tamary, O. Dgany, A. Proust, T. Krasnov, N. Avidan, T. Eidelitz-Markus, G. Tchernia, D. Geneviève, V. Cormier-Daire, B. Bader-Meunier, C. Ferrero-Vacher, M. Munzer, R. Gruppo, E. Fibach, O. Konen, I. Yaniv and J. Delaunay

635 **Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry–mass spectrometry**
Y. A. Daniel, C. Turner, R. M. Haynes, B. J. Hunt and R. N. Dalton

Short report 644 **Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection**
A. Inati, A. Taher, S. Ghorra, S. Koussa, M. Taha, E. Aoun and A. I. Sharara

Correspondence

647 **Absence of fibrinogen α-, β- and γ-chain mRNA in human platelets**
J. M. Rox, J. Müller and B. Pötzsch

648 **Clustering and anticipation for nodular lymphocyte predominance Hodgkin lymphoma within a French Basque kindred**
F. Bauduer, J. Vassallo, G. Delsol and P. Brousset

Book review

650 **Case-based Haematology**
M. Lewis

Issue 5, September-I 2005

Images in Haematology

651 **Multiple Pappenheimer bodies**
A. J. Fyfe and R. L. Soutar

652 **Bone marrow metastasis of small cell carcinoma of the lung mimicking Burkitt lymphoma/leukaemia**
T. Iguchi, N. Awaya, K. Kobayashi and S. Okamoto

Reviews

653 **The measurement and application of thrombin generation**
T. Baglin

662 **AIDS-related lymphomas: from pathogenesis to pathology**
A. Carbone and A. Gloghini

671 **Air travel and thrombosis**
Y.-L. Chee and H. G. Watson

Haematological Malignancy

681 **Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells**
K. Suzuki, R. Adachi, A. Hirayama, H. Watanabe, S. Otani, Y. Watanabe and T. Kasahara

691 **Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999**
P. A. Hamlin, C. S. Portlock, D. J. Straus, A. Noy, A. Singer, S. M. Horwitz, O. A. OConnor, J. Yahalom, A. D. Zelenetz and C. H. Moskowitz

700 **Identification of *ID-1* as a potential target gene of *MMSET* in multiple myeloma**
H. R. Hudlebusch, K. Theilgaard-Mönch, M. Lodahl, H. E. Johnsen and T. Rasmussen

709 **Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases**
K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta, A. Katsaraki, K. Seferiadis, J. Stebbing and K. L. Bourantas

716 **Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias**
G. Tabellini, P. L. Tazzari, R. Bortul, C. Evangelisti, A. M. Billi, T. Grafone, G. Martinelli, M. Baccarani and A. M. Martelli

Short reports

726 **Acute myeloid leukaemia with *FLT3* gene mutations of both internal tandem duplication and point mutation type**
W. Chen, D. Jones, L. J. Medeiros, R. Luthra and P. Lin

729 **Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma**
L. Rosiñol, A. Carrió, J. Bladé, R. Queralt, M. Aymerich, M. Cibeira, J. Esteve, M. Rozman, E. Campo and E. Montserrat

Transplantation

733 **Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning**
A. Montero, B. N. Savani, R. Kurlander, E. J. Read, S. F. Leitman, R. Childs, S. R. Solomon and A. J. Barrett

740 **Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors**
J. C. Fischer, M. Frick, R. Wassmuth, A. Platz, M. Punzel and P. Wernet

Short report

747 **Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up**
C. Kahl, W. Leisenring, H. J. Deeg, T. R. Chauncey, M. E. D. Flowers, P. J. Martin, J. E. Sanders and R. Storb

Platelets, Haemostasis and Thrombosis

752 **Gene conversions are a common cause of von Willebrand disease**
P. K. Gupta, E. Adamtziki, U. Budde, M. Jaiprakash, H. Kumar, A. Harbeck-Seu, M. Kannan, F. Oyen, T. Obser, I. Wedekind, R. Saxena and R. Schneppenheim

759 **Variables influencing Platelet Function Analyzer-100™ closure times in healthy individuals**
H. Haubelt, C. Anders, A. Vogt, P. Hoerdt, U. T. Seyfert and P. Hellstern

768 **Splenectomy for the treatment of thrombotic thrombocytopenic purpura**
M. C. Kappers-Klunne, P. Wijermans, R. Fijnheer, A. J. Croockewit, B. van der Holt, J. T. M. de Wolf, B. Löwenberg and A. Brand

777 **Complimentary and alternative medicine use among patients starting warfarin**
N. A. Ramsay, M. W. Kenny, G. Davies and J. P. Patel

Transfusion

781 **Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children**
R. P. Sanders, S. D. Maddirala, T. L. Geiger, S. Pounds, J. T. Sandlund, R. C. Ribeiro, C.-H. Pui and S. C. Howard

Short reports

788 **Ligation of CD47 mediates phosphatidylserine expression on erythrocytes and a concomitant loss of viability *in vitro***
D. J. Head, Z. E. Lee, M. M. Swallah and N. D. Avent

791 **Tracking and characterisation of transfused platelets by two colour, whole blood flow cytometry**
D. L. Hughes, G. Evans, P. Metcalfe, A. H. Goodall and L. M. Williamson

Correspondence

795 **MBL and MoBL**
L. Ziegler-Heitbrock

795 **MBL and MoBL – Response to Ziegler-Heitbrock**
G. E. Marti, A. C. Rawstron, P. Ghia, P. Hillmen, R. S. Houlston, N. Kay, T. A. Schleinitz and N. Caporaso

796 **Inherited *FANCD1/BRCA2* exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia**
L. M. Barber, R. A. Barlow, S. Meyer, D. J. White, A. M. Will, T. O. B. Eden and G. M. Taylor

797 **Mutation studies in $CD3^+$, $CD19^+$ and $CD34^+$ cell fractions in myeloproliferative disorders with homozygous $JAK2^{V617F}$ in granulocytes**
T. L. Lasho, R. Mesa, D.G. Gilliland and A. Tefferi

800 **The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera**
H. Cario, P. S. Goerttler, C. Steimle, R. L. Levine and H. L. Pahl

801 **Differences in the prevalence of *PTPN11* mutations in FAB M5 paediatric acute myeloid leukaemia**
B. F. Goemans, Ch. M. Zwaan, S. Martinelli, P. Harrell, D. de Lange, C. Carta, D. Reinhardt, K. Hählen, U. Creutzig, M. Tartaglia, M. C. Heinrich and G. J. L. Kaspers

803 **Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis**
C. Aguilar and V. del Villar

805 **Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis: response to Aguilar & del Villar**
R. Schutgens and D. Biesma

Announcement

806 **MRCPath Haemostasis Training and Update**

Issue 6, September-II 2005

Images in Haematology

807 **G-CSF stimulated islands of haematopoiesis mimicking disseminated malignancy on PET-CT and MRI scans in a patient with hypoplastic marrow disorder**
M. Kouba, J. Maaloufova, V. Campr, O. Belohlavek and B. Drugova

808 **Progressive multifocal leucoencephalopathy in a case of chronic lymphocytic leukaemia**
M. M. Hasan and P. Taylor

Reviews

809 **Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily**
K. S. Peggs and J. P. Allison

825 **Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia**
D. A. Breems and B. Löwenberg

Annotation

834 **Sir John Dacie MD, FRS, FRCP, FRCPath**
M. Lewis

Haematological Malignancy

845 **t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations**
H. V. Aamot, M. Bjørnslett, J. Delabie and S. Heim

852 **Expression of *C-IAP1*, *C-IAP2* and *SURVIVIN* discriminates different types of lymphoid malignancies**
A. O. de Graaf, J. H. van Krieken, E. Tönnissen, W. Wissink, L. van de Locht, I. Overes, H. Dolstra, T. de Witte, B. A. van der Reijden and J. H. Jansen

860 **Selective apoptosis of natural killer-cell tumours by L-asparaginase**
M. Ando, K. Sugimoto, T. Kitoh, M. Sasaki, K. Mukai, J. Ando, M. Egashira, S. M. Schuster and K. Oshimi

869 **Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C**
I. Kadowaki, R. Ichinohasama, H. Harigae, K. Ishizawa, Y. Okitsu, J. Kameoka and T. Sasaki

878 **Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line**
S. Minuzzo, S. Indraccolo, V. Tosello, E. Piovan, A. Cabrelle, L. Trentin, G. Semenzato and A. Amadori

890 **G-banding and molecular cytogenetic analyses of marginal zone lymphoma**
H. V. Aamot, F. Micci, H. Holte, J. Delabie and S. Heim

902 **The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity**
A. Kilbey, H. Alzuherri, J. McColl, C. Calés, J. Frampton and C. Bartholomew

Haemopoiesis and Leucocytes

912 **Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells**
M. A. Morgan, T. Sebil, E. Aydilek, D. Peest, A. Ganser and C. W. M. Reuter

926 **Functional osteoclast-like transformation of cultured human myeloma cell lines**
N. Calvani, P. Cafforio, F. Silvestris and F. Dammacco

Red Cells and Iron

939 **The frequency of the sickle allele in Jamaica has not declined over the last 22 years**
N. A. Hanchard, I. Hambleton, R. M. Harding and C. A. McKenzie

943 **Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality**
G. J. Kato, S. Martyr, W. C. Blackwelder, J. S. Nichols, W. A. Coles, L. A. Hunter, M.-L. Brennan, S. L. Hazen and M. T. Gladwin

Transfusion

954 **Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method**
G. Stussi, K. Huggel, H. U. Lutz, U. Schanz, R. Rieben and J. D. Seebach

Correspondence

964 **The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia**
S. Sulong, M. Case, L. Minto, B. Wilkins, A. Hall and J. Irving

965 **Risk factors for highly unstable response to oral anticoagulation**
P. T. Murphy

966 **Risk factors for highly unstable response to oral anticoagulation: response to Murphy**
B. Cosmi and G. Palareti

966 **Low CD4/CD8 ratios in human immunodeficiency virus-negative haemophilia patients cause high hepatitis C viraemia**
K. Meijer, S. Kalk, W. M. Smid and J. van der Meer

968 ***JAK2* V617F Mutation is uncommon in chronic myelomonocytic leukaemia**
M. F. Johan, A. C. Goodeve, D. T. Bowen, M. E. Frew and J. T. Reilly

969 **Del(9q) acute myeloid leukaemia: clinical and cytological characteristics and prognostic implications**
D. Catovsky and J. Swansbury

969 **Del(9q) acute myeloid leukaemia: clinical and cytological characteristics and prognostic implications – response to Catovsky and Swansbury**
A. J. Peniket

970 **Long-term follow-up of Philadelphia chromosome-positive (Ph^+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period**
F. Giona, M. L. Moleti, I. Del Giudice, A. M. Testi, D. Diverio, M. R. De Cuia, F. Mandelli and R. Foà

973 **Corrigendum**

973 **Erratum**

974 **Author Index**

978 **Keyword Index**